ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
USA - NASDAQ:ASTH - US03763A2078 - Common Stock
31.21 USD
-0.6 (-1.89%)
31.21 USD
0 (0%)
Taking everything into account, ASTH scores 5 out of 10 in our fundamental rating. ASTH was compared to 101 industry peers in the Health Care Providers & Services industry. While ASTH seems to be doing ok healthwise, there are quite some concerns on its profitability. ASTH is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
In the past year ASTH had a positive cash flow from operations.
In the past 5 years ASTH has always been profitable.
In the past 5 years ASTH always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 1.75%, ASTH perfoms like the industry average, outperforming 56.44% of the companies in the same industry.
The Return On Equity of ASTH (3.30%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 4.50%, ASTH is in line with its industry, outperforming 53.47% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ASTH is below the industry average of 9.33%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROIC | 4.5% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
ASTH has a Profit Margin (1.04%) which is comparable to the rest of the industry.
ASTH's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 2.90%, ASTH perfoms like the industry average, outperforming 54.46% of the companies in the same industry.
In the last couple of years the Operating Margin of ASTH has declined.
Looking at the Gross Margin, with a value of 11.30%, ASTH is doing worse than 72.28% of the companies in the same industry.
ASTH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ASTH has more shares outstanding
ASTH has a worse debt/assets ratio than last year.
2.2 Solvency
ASTH has an Altman-Z score of 3.74. This indicates that ASTH is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.74, ASTH is in the better half of the industry, outperforming 70.30% of the companies in the same industry.
ASTH has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ASTH would need 3.41 years to pay back of all of its debts.
ASTH's Debt to FCF ratio of 3.41 is fine compared to the rest of the industry. ASTH outperforms 76.24% of its industry peers.
ASTH has a Debt/Equity ratio of 0.52. This is a neutral value indicating ASTH is somewhat dependend on debt financing.
The Debt to Equity ratio of ASTH (0.52) is better than 60.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.74 |
ROIC/WACC0.49
WACC9.12%
2.3 Liquidity
ASTH has a Current Ratio of 1.59. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ASTH (1.59) is comparable to the rest of the industry.
A Quick Ratio of 1.59 indicates that ASTH should not have too much problems paying its short term obligations.
ASTH has a Quick ratio of 1.59. This is comparable to the rest of the industry: ASTH outperforms 58.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 |
3. Growth
3.1 Past
The earnings per share for ASTH have decreased strongly by -64.58% in the last year.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
ASTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 51.97%.
Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
3.2 Future
ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.87% yearly.
Based on estimates for the next years, ASTH will show a very strong growth in Revenue. The Revenue will grow by 20.51% on average per year.
EPS Next Y37.27%
EPS Next 2Y52.57%
EPS Next 3Y45.45%
EPS Next 5Y31.87%
Revenue Next Year61.55%
Revenue Next 2Y43.26%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 61.20 indicates a quite expensive valuation of ASTH.
ASTH's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.10, ASTH is valued quite expensively.
A Price/Forward Earnings ratio of 15.06 indicates a correct valuation of ASTH.
ASTH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 76.24% of the companies in the same industry.
ASTH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.52.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.2 | ||
| Fwd PE | 15.06 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
ASTH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ASTH is cheaper than 83.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.85 | ||
| EV/EBITDA | 16.4 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 45.45% in the coming years.
PEG (NY)1.64
PEG (5Y)3.19
EPS Next 2Y52.57%
EPS Next 3Y45.45%
5. Dividend
5.1 Amount
No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.21
-0.6 (-1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.14%
Inst Owner ChangeN/A
Ins Owners9.76%
Ins Owner Change0.19%
Market Cap1.56B
Revenue(TTM)2.42B
Net Income(TTM)25.26M
Analysts85
Price Target45.9 (47.07%)
Short Float %4.3%
Short Ratio5.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP33.15%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.54%
Min EPS beat(2)-48.7%
Max EPS beat(2)-44.39%
EPS beat(4)1
Avg EPS beat(4)-79.13%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)5
Avg EPS beat(8)-25.47%
EPS beat(12)8
Avg EPS beat(12)-7.32%
EPS beat(16)11
Avg EPS beat(16)2.37%
Revenue beat(2)1
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)0.57%
Revenue beat(4)3
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.88%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.88%
EPS NY rev (1m)0%
EPS NY rev (3m)0.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.2 | ||
| Fwd PE | 15.06 | ||
| P/S | 0.64 | ||
| P/FCF | 12.85 | ||
| P/OCF | 11.94 | ||
| P/B | 2.04 | ||
| P/tB | 6.42 | ||
| EV/EBITDA | 16.4 |
EPS(TTM)0.51
EY1.63%
EPS(NY)2.07
Fwd EY6.64%
FCF(TTM)2.43
FCFY7.78%
OCF(TTM)2.61
OCFY8.38%
SpS48.45
BVpS15.33
TBVpS4.86
PEG (NY)1.64
PEG (5Y)3.19
Graham Number13.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROCE | 7.13% | ||
| ROIC | 4.5% | ||
| ROICexc | 6.9% | ||
| ROICexgc | 37.52% | ||
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% | ||
| FCFM | 5.01% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 4.04 | ||
| Cap/Depr | 31.97% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 8.53 | ||
| Cash Conversion | 131.6% | ||
| Profit Quality | 480.02% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 | ||
| Altman-Z | 3.74 |
F-Score5
WACC9.12%
ROIC/WACC0.49
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
EPS Next Y37.27%
EPS Next 2Y52.57%
EPS Next 3Y45.45%
EPS Next 5Y31.87%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
Revenue Next Year61.55%
Revenue Next 2Y43.26%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
EBIT growth 1Y-26.57%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year116.25%
EBIT Next 3Y48.23%
EBIT Next 5Y33.37%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A
ASTRANA HEALTH INC / ASTH FAQ
Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?
ChartMill assigns a fundamental rating of 5 / 10 to ASTH.
What is the valuation status for ASTH stock?
ChartMill assigns a valuation rating of 5 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.
How profitable is ASTRANA HEALTH INC (ASTH) stock?
ASTRANA HEALTH INC (ASTH) has a profitability rating of 3 / 10.
What is the financial health of ASTRANA HEALTH INC (ASTH) stock?
The financial health rating of ASTRANA HEALTH INC (ASTH) is 5 / 10.
Is the dividend of ASTRANA HEALTH INC sustainable?
The dividend rating of ASTRANA HEALTH INC (ASTH) is 0 / 10 and the dividend payout ratio is 33.15%.